Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000358 · ClinicalTrials.gov registry record · Phase 1

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

A Phase 1 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00000358: Completed Phase 1 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).

NCT00000358 is a Phase 1 study of Substance-Related Disorders and Opioid-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000358, a Phase 1 study of Substance-Related Disorders and Opioid-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

Conditions Studied

Substance-Related Disorders Opioid-Related Disorders

Interventions

  • DRUG Lofexidine

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Phase Phase 1
National Institute on Drug Abuse (NIDA)

335 total trials

What the finished NCT00000358 record still lists

NCT00000358 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Lofexidine is the first listed.

NCT00000358 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00000358 about?

NCT00000358 is a clinical study titled "Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7". The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

What is the current status of trial NCT00000358?

This trial is currently completed. It is a Phase 1 study.

What conditions does trial NCT00000358 study?

This clinical trial studies the following conditions: Substance-Related Disorders, Opioid-Related Disorders.

What interventions are being tested in trial NCT00000358?

The interventions under investigation include: Lofexidine (DRUG).

Who is sponsoring clinical trial NCT00000358?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000358 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Substance-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00000358, the US trial registry maintained by the National Library of Medicine. NCT00000358 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.